相关临床试验
1422
136 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1861
Unknown
74
5.2%
已完成
899
63.2%
Enrolling By Invitation
18
1.3%
尚未招募
41
2.9%
No Longer Available
1
0.1%
终止
108
7.6%
招募中
172
12.1%
暂停
1
0.1%
撤回
31
2.2%
进行中（未招募）
77
5.4%
暂无批准数据
- The U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand Biosciences and the University of Washington in their patent infringement suit against Guardant Health. - The judgment preserves a November 2023 jury verdict finding Guardant Health willfully infringed two Duplex Sequencing patents across 11 royalty-bearing products and services. - TwinStrand and UW were awarded more than $245.2 million in damages, accrued royalties, and interest, with a 6% royalty ordered on covered sales through patent expiration on March 15, 2033. - The court upheld the validity of both asserted patents, US Patent Nos. 10,287,631 and 10,760,127, reinforcing the strength of TwinStrand's Duplex Sequencing intellectual property.
- The Marcus Foundation has awarded Chuck Murry, MD, PhD, of USC Stem Cell Center $28.7 million to advance a clinical trial of a stem cell-based therapy for regenerating heart muscle after a heart attack. - The pioneering trial will begin at Keck Hospital in 2027 in partnership with the USC Cardiac and Vascular Institute, with a second site at the University of Washington. - The study will enroll about 18 patients with severe heart attacks and primarily assess safety and feasibility of delivering stem-cell-derived heart muscle cells into damaged heart regions. - The award, the largest the foundation has given to USC, will also fund parallel research on the immune response to cell transplantation to reduce or eliminate the need for immunosuppressive drugs.
- A novel AI model developed through the Cleveland Clinic-IBM Discovery Accelerator identifies hidden sleep patterns linked to heart disease, cognitive decline, and death from routine polysomnography data. - Patients in the highest-risk group had twice the five-year mortality risk compared to the lowest-risk group, a distinction not captured by the standard apnea-hypopnea index. - The model performed well for both men and women, addressing a known limitation of the apnea-hypopnea index which historically performs better in men. - Findings, published in Nature Communications and validated in a nationwide cohort, suggest routine medical tests may contain substantially more physiological information than current clinical practice extracts.
- The Gates Foundation granted $540 million over 10 years to the Institute for Health Metrics and Evaluation (IHME) at the University of Washington to strengthen freely available, scientifically rigorous health evidence. - The funding aims to support governments, researchers, and leaders in improving health and well-being across Washington state and worldwide. - The grant underscores the role of philanthropy in funding life-saving research institutes and programs for patients with common and rare diseases. - University of Washington Department of Medicine leadership highlighted philanthropy as a game-changer for clinical care, education, and research infrastructure.
- Ischemic heart disease deaths in the U.S. fell by 58.7% from 1990 to 2023, driven largely by reductions in smoking and particulate air pollution, according to a JAMA Cardiology study. - Despite progress, 88.8% of the estimated 473,000 coronary artery disease deaths in 2023 were attributable to modifiable risk factors, led by high systolic blood pressure (47.2%), dietary risks (38.6%), and high LDL cholesterol (28.5%). - Deaths linked to high BMI and high fasting blood glucose have risen by 12.5% and 10.5% respectively since 1990, signaling growing challenges from obesity and diabetes. - Researchers and editorialists call for policy interventions, improved communication, and wider use of generic medicines to address the cardiovascular-kidney-metabolic syndrome and persistent geographic disparities.
- New research published in The Journal of Immunology identifies biomarkers of a distinct immune profile that could identify trauma patients at risk for chronic critical illness (CCI) upon ICU admission. - Contrary to long-held beliefs about immune exhaustion, the study reveals that CCI is driven by immune overactivity and dysfunction, including elevated neutrophils, Th17 cells, IFNγ, and IL-17A. - IL-17A emerged as the most informative marker distinguishing CCI patients, with some showing elevated levels as early as day 1 in the ICU, suggesting almost immediate immune dysregulation. - Developing a test for this immune profile could allow clinicians to tailor patient care, quickening recovery time and potentially saving lives.
- An international team led by POSTECH's Prof. Sangmin Lee and Nobel laureate Prof. David Baker used AI to design artificial proteins that self-assemble into virus-like nanocages ranging from 70 to 220 nm. - The breakthrough, published in Nature, successfully implements the natural principle of quasisymmetry, enabling a single protein to form both pentagonal and hexagonal arrangements. - The AI-designed nanocages represent a promising next-generation platform for targeted drug delivery, genetic material transport, and vaccine antigen presentation. - Two related papers were published simultaneously in Nature, with Prof. Lee serving as corresponding author on one and co-author on the other — a rare dual achievement.
- VA Community Care referrals for vascular surgery nearly tripled from 21,407 in FY2020 to 62,487 in FY2025, a 192% increase driven largely by peripheral artery disease interventions. - Infrainguinal endovascular procedure payments more than quadrupled from $8.8 million to $40.2 million, with femoral-popliteal atherectomy as the highest-paid procedure code across nearly all years analyzed. - Distance from a VA facility accounted for 88% of community care referrals, and no open bypass or groin-level reconstruction procedures appeared among the top 30 paid codes. - Researchers emphasize the need for comparative effectiveness research to guide evidence-based treatment decisions as endovascular spending dominates VA Community Care vascular surgery costs.
- CorTec GmbH has received FDA Breakthrough Device Designation for its Brain Interchange system, marking the first BCI worldwide designated specifically for stroke motor rehabilitation. - The fully implantable, wireless system combines neural signal recording with adaptive stimulation in a closed-loop design and is currently being evaluated in the first human clinical trial at the University of Washington. - With approximately 9 million ischemic strokes occurring globally each year and over 50% of survivors remaining permanently disabled despite standard rehabilitation, the designation addresses a significant unmet medical need. - CorTec's therapeutic approach differentiates it from other BCI companies that focus primarily on assistive communication, as it aims to physically restore motor function through neurostimulation.
- The University of Washington is enrolling volunteers in the BEETHOVEN study, a Phase 3 trial testing an investigational Clostridioides difficile vaccine for adults 65 and older at increased risk of infection. - The multi-site trial involves 129 locations across the United States and other countries, with participants receiving two vaccine doses and being monitored for up to three and a half years. - C. diff is a leading cause of healthcare-acquired infections that can cause severe diarrhea, hospitalization, and life-threatening complications, particularly affecting older adults with recent antibiotic use or frequent healthcare exposure. - The vaccine aims to address a significant unmet medical need by preventing C. diff infections in vulnerable populations who face this "dreaded complication" of hospital stays and antibiotic treatments.
